Cardiology – Notable Articles of 2023 – Part 2

Rosuvastatin vs. Atorvastatin; Bempedoic Acid; Immediate versus staged PCI; Stroke Anticoagulation; Semaglutide in Obesity without Diabetes Resources: Rosuvastatin vs. Atorvastatin Treatment in Patients With Coronary Artery Disease – LODESTAR https://www.bmj.com/content/383/bmj-2023-075837 https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/08/23/19/37/lodestar Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients - CLEAR Outcomes trial https://www.nejm.org/doi/full/10.1056/NEJMoa2215024 https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/03/01/23/31/clear-outcomes Immediate versus staged complete revascularization in patients presenting with acute coronary syndrome and multivessel coronary disease: a prospective, open-label, non-inferiority, randomized trial - BIOVASC https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00351-3/fulltext https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/03/01/23/40/biovasc Early versus Later Anticoagulation for Stroke with Atrial Fibrillation – ELAN trial https://www.nejm.org/doi/full/10.1056/NEJMoa2303048 https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/05/24/17/31/elan Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes – SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/11/09/15/04/select

Om Podcasten

MediBlurb is a physician-directed organization viewed as the authoritative strategy to “briefly announce” important information regarding the latest advances in medical care and research, along with reports pertaining to medical devices and pharmaceuticals. Information is derived from trustworthy and respected medical sources.